COMMUNIQUÉS West-GlobeNewswire

BrainsWay Receives PMDA Approval in Japan of Deep Transcranial Magnetic Stimulation System for Treatment of Major Depressive Disorder
29/01/2019
Approval allows BrainsWay’s Deep TMS System to be marketed throughout Japan JERUSALEM, Jan. 29, 2019 (GLOBE NEWSWIRE) -- BrainsWay Ltd. (TASE: BRIN) , a global leader in the advanced non-invasive treatment of brain [...]
Altimmune Announces Presentation of HepTcell Phase 1 Results at The International Liver Congress™ in Vienna, Austria
29/01/2019
GAITHERSBURG, Md., Jan. 29, 2019 (GLOBE NEWSWIRE) -- Altimmune, Inc. (Nasdaq: ALT), a clinical-stage immunotherapeutics company, today announced results of its recently completed HepTcell Phase 1 clinical trial will be [...]
Precipio Gains Recognition on NY Radio Station WHPC Show “My Hometown” As Innovator Battling Cancer Misdiagnosis
29/01/2019
CEO Ilan Danieli discusses the importance of obtaining an accurate diagnosis, and the challenges patients and physicians face NEW HAVEN, Conn., Jan. 29, 2019 (GLOBE NEWSWIRE) -- Specialty cancer diagnostics company [...]
Auris Medical to Redomicile Holding Company from Switzerland to Bermuda
29/01/2019
Move to Bermuda will enhance corporate flexibility, reduce costs and provide better alignment with U.S. corporate law Subject to approval by extraordinary general meeting of shareholders Zug, Switzerland, January 29, [...]
KemPharm Announces Enhancements to U.S. and Global Intellectual Property Estate
29/01/2019
Patents Extend Across KemPharm’s Prodrug Portfolio, Including IP Protection for KP415 in Canada, Japan and Korea CELEBRATION, Fla., Jan. 29, 2019 (GLOBE NEWSWIRE) -- KemPharm, Inc. (NASDAQ: KMPH), a specialty [...]
National Healthcare Economics and Policy Expert Ruben Jose King-Shaw Jr Joins CURE Pharmaceutical’s Board of Directors
29/01/2019
The drug delivery leader taps former COO of U.S. Centers for Medicare & Medicaid Services to join growing Board OXNARD, Calif., Jan. 29, 2019 (GLOBE NEWSWIRE) -- CURE Pharmaceutical (OTC: CURR), an innovative drug [...]
IMV Announces Clinical Update for DPX-Survivac Program in Ovarian Cancer Following Positive Feedback from U.S. FDA
29/01/2019
DECIDE phase 2 clinical trial amendment successfully completed with multiple sites now open for enrollment FDA provided guidance for future registration trial design and for a potential shorter regulatory pathway for [...]
Neurocrine Biosciences and Voyager Therapeutics Form Strategic Development and Commercialization Collaboration for Parkinson’s Disease and Friedreich’s Ataxia
29/01/2019
Collaboration leverages strengths and efforts of both companies towards developing and commercializing life-changing treatments for severe neurological diseases Neurocrine Biosciences gains development and [...]
Aravive to Host Key Opinion Leader Breakfast Symposium on AVB-S6-500 and the GAS6-AXL Pathway on February 5, 2019
29/01/2019
HOUSTON, Jan. 29, 2019 (GLOBE NEWSWIRE) -- Aravive, Inc. (Nasdaq: ARAV), a clinical-stage biopharmaceutical company, today announced that it will host a key opinion leader (KOL) symposium focused on the GAS6-AXL pathway [...]
FACIT and Triphase Accelerator Announce New Partnership with Celgene for First-in-class WDR5 Leukemia Therapy
29/01/2019
Largest transaction to date for Canadian-discovered preclinical asset arises from Ontario collaborators TORONTO, ON, Jan. 29, 2019 (GLOBE NEWSWIRE) -- Triphase Accelerator, together with its majority shareholder FACIT, [...]
LHC Group Appoints National Healthcare Veteran Teri G. Fontenot to Board of Directors
29/01/2019
LAFAYETTE, La., Jan. 29, 2019 (GLOBE NEWSWIRE) -- LHC Group, Inc. (NASDAQ: LHCG) announced today that it has appointed Teri G. Fontenot to the Board of Directors, effective March 1, 2019. Ms. Fontenot, who will serve as [...]
Emerald Health Therapeutics’ Licensed Endo Product Line Gains Boost with Entry into Whole Foods Market Stores Across US
29/01/2019
Emerald Health Therapeutics and Emerald Health Naturals on track to launch endocannabinoid-supporting products in Canada VICTORIA, British Columbia, Jan. 29, 2019 (GLOBE NEWSWIRE) -- Emerald Health Therapeutics, Inc. (“ [...]
Managers’ transactions
29/01/2019
Company Announcement No. 3/2019 January 29, 2019 For further information please contact: Martin Riise, Senior Director, Investor Relations, Tel: +45 5339 2250 Camilla Lercke, Head of Media Relations, Tel: +45 5339 2384 [...]
Nicox : Aval de la FDA américaine pour l'Investigational New Drug du NCX 4251 pour une étude de phase 2 dans la blépharite
29/01/2019
Communiqué de presse Nicox : Aval de la FDA américaine pour l'Investigational New Drug du NCX 4251 pour une étude de phase 2 dans la blépharite ................................................. 29 janvier 2019 - [...]
Nicox Announces U.S. FDA Acceptance of Investigational New Drug Application for NCX 4251 Phase 2 Trial in Blepharitis
29/01/2019
Press Release Nicox Announces U.S. FDA Acceptance of Investigational New Drug Application for NCX 4251 Phase 2 Trial in Blepharitis ................................................ January 29 th , 2019 - release at 7:30 [...]
Biocartis Group NV: DISCLOSURE OF OUTSTANDING VOTING SECURITIES
29/01/2019
PRESS RELEASE : REGULATED INFORMATION 29 January 2019, 07:00 CET Disclosure of Outstanding Voting Securities Mechelen, Belgium, 29 January 2019 - Biocartis Group NV (the 'Company' or 'Biocartis'), an innovative [...]
INNATE PHARMA RECEIVES FDA FAST TRACK DESIGNATION FOR IPH4102 IN RELAPSED OR REFRACTORY SÉZARY SYNDROME
29/01/2019
INNATE PHARMA RECEIVES FDA FAST TRACK DESIGNATION FOR IPH4102 IN RELAPSED OR REFRACTORY SÉZARY SYNDROME Fast Track designation (FTD) is intended to expedite the development and regulatory review of IPH4102 for the [...]
INNATE PHARMA REÇOIT LE STATUT « FAST TRACK » DE LA FOOD AND DRUG ADMINISTRATION (FDA) POUR IPH4102 CHEZ LES PATIENTS PRÉSENTANT UN SYNDROME DE SÉZARY EN RECHUTE OU RÉFRACTAIRE
29/01/2019
INNATE PHARMA REÇOIT LE STATUT « FAST TRACK » DE LA FOOD AND DRUG ADMINISTRATION (FDA) POUR IPH4102 CHEZ LES PATIENTS PRÉSENTANT UN SYNDROME DE SÉZARY EN RECHUTE OU RÉFRACTAIRE Le statut « Fast Track » vise à accélérer [...]
Cancer Genetics, Inc. Announces Pricing of $3.5 Million Public Offering of Common Stock
29/01/2019
RUTHERFORD, N.J., Jan. 28, 2019 (GLOBE NEWSWIRE) -- Cancer Genetics, Inc. (Nasdaq: CGIX), a leader in enabling precision medicine for immuno-oncology and genomic medicine through molecular markers and diagnostics, today [...]

Pages